LC
NTLA icon

Lindbrook Capital’s Intellia Therapeutics NTLA Stock Holding History

Lindbrook Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$10.3K Buy
1,446
+1,383
+2,195% +$14K ﹤0.01% 1639
2024
Q4 		$735 Sell
63
-24
-28% -$375 ﹤0.01% 2534
2024
Q3 		$1.79K Sell
87
-176
-67% -$4.06K ﹤0.01% 2384
2024
Q2 		$5.89K Sell
263
-283
-52% -$6.74K ﹤0.01% 1916
2024
Q1 		$15K Sell
546
-59
-10% -$1.64K ﹤0.01% 1363
2023
Q4 		$18.4K Buy
605
+380
+169% +$10.9K ﹤0.01% 1219
2023
Q3 		$7.12K Buy
225
+48
+27% +$1.86K ﹤0.01% 1586
2023
Q2 		$7.22K Buy
177
+92
+108% +$3.73K ﹤0.01% 1636
2023
Q1 		$3.17K Sell
85
-31
-27% -$1.22K ﹤0.01% 2048
2022
Q4 		$4.05K Sell
116
-123
-51% -$5.85K ﹤0.01% 1928
2022
Q3 		$13K Buy
239
+21
+10% +$1.3K ﹤0.01% 1205
2022
Q2 		$11K Sell
218
-12
-5% -$609 ﹤0.01% 1223
2022
Q1 		$17K Sell
230
-370
-62% -$31.3K ﹤0.01% 1077
2021
Q4 		$71K Buy
600
+552
+1,150% +$69.2K 0.01% 605
2021
Q3 		$6K Hold
48
– – ﹤0.01% 1202
2021
Q2 		$8K Sell
48
-97
-67% -$7.55K ﹤0.01% 1144
2021
Q1 		$12K Buy
+145
New +$9.73K ﹤0.01% 947
2020
Q3 		– Sell
-187
Closed -$4K – 1819
2020
Q2 		$4K Buy
+187
New +$3.18K ﹤0.01% 1186

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lindbrook Capital's NTLA Position: Q1 2025 in Review

Lindbrook Capital increased its Intellia Therapeutics (NTLA) stake by 2,195% in Q1 2025, buying an estimated $14K and bringing the position to 1,446 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

Lindbrook Capital first reported a position in NTLA in Q2 2020 and has held it in 18 quarters since. The position peaked at $71K in Q4 2021. 295 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Lindbrook Capital held 1,446 shares of Intellia Therapeutics worth $10.3K as of Q1 2025.
  • Lindbrook Capital bought 1,383 Intellia Therapeutics shares in Q1 2025, an estimated $14K.
  • Intellia Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1639 holding.
  • Lindbrook Capital first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • Lindbrook Capital's Intellia Therapeutics position peaked at $71K in Q4 2021.
  • 295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.